Kesimpta® (ofatumumab) granted European and UK license for relapsing multiple sclerosis
Novartis (London, UK) has announced that the Medicines and Healthcare products Regulatory Agency (MHRA), alongside the European Commission, has granted a marketing authorization for the use of ofatumumab for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with RMS with active disease, defined by clinical or imaging features. It has the potential to become a recognized treatment option for eligible UK patients with RMS that can be self-administered, with initial guidance from an appropriately trained healthcare professional, once monthly at home via the...